Patients considering transitioning to Retatrutide should consult with healthcare providers for timing, coordination, medication management, monitoring, lifestyle adjustments, and active engagement in the treatment plan for optimal benefits and well-being
A number of different fecal microbiota transplant methods are under investigation, including direct infusion of prepared fecal matter into the gastrointestinal tract and encapsulation of a highly refined preparation for oral administration
Since retatrutide does not hold MHRA or EMA marketing authorisation, no SmPC, PIL, or NICE guidance specific to this compound is available to the public
Rather quietly this week, Eli Lilly and Company announced that it had withdrawn an application to FDA for an indication to use tirzepatide (Zepbound) in treating heart failure specifically for HFpEF